To determine whether IL-2 potentiates the cetuximab-mediated outcome on restored effector cell cytotoxicity against HNSCC cells, we analyzed the degree of ADCC from X-VIVOTM10-, PP-, and HP-treated patient NK cells against cetuximab-coated and non-labeled HNSCC cells in the presence or absence of IL-2 (Figure 4E). The gene discussed is IL2; the disease is head and neck squamous cell carcinoma.